Session I - BASIC/TRANSLATIONAL SCIENCE SHAPING THE FUTURE OF TARGETED THERAPIES

Charimen: R. Foà (Roma), G. Gaidano (Novara)

Session II - ACADEMIC RESEARCH LEADING TO CHANGE IN CLINICAL PRACTICE: THREE MILESTONES

Interim FDG-PET in advanced classical Hodgkin lymphoma: will the story continue? - M. Hutchings (Copenhagen, DK)
Primary mediastinal B-cell lymphoma - M. Martelli (Roma)
Session III - CHANGING TREATMENT ALGORITHMS IN TREATMENT OF AGGRESSIVE LYMPHOMAS

Chairmen: P. Corradini (Milano), M. Martino (Reggio Calabria)

Introductory key lecture: rethinking treatment algorithms in aggressive B-cell lymphomas - L. Sehn (Vancouver, CAN)
Novel pharmacological paradigms in aggressive B-cell lymphomas - G. Minotti (Roma)
Antibody non drug and drug-conjugated - C. Carlo-Stella (Rozzano, MI)
CAR-T follicular and DLBC lymphoma - A. Di Rocco (Roma)
Session IV - DIFFICULT-TO-DIAGNOSE AND DIFFICULT-TO-TREAT LYMPHOMAS

Charimen: M. Spina (Aviano, PN), U. Vitolo (Candiolo, TO)

Gray-zone Lymphomas: Diagnosis - C. Agostinelli (Bologna)
Gray-zone Lymphomas: Treatment - A. Broccoli (Bologna)
The double-hit and the double expressor: Treatment - M. Balzarotti (Milano)
Mantle cell lymphoma with poor prognosis (blastoid morphology, p53 mutation, high proliferation index): How can we exploit target therapies (BKTi, BCL2i, T-cell-engagers)? - C. Visco (Verona)
Session V - LYMPHOMAS WITH GOOD PROGNOSIS: DO NOT HARM

Chairman: G. Gini (Ancona)

Introductory key lecture: the indolent lymphomas - C. Thieblemont (Paris, FR)
Follicular lymphoma - S. Montoto (London, UK)
Marginal zone lymphoma - E. Zucca (Bellinzona, CH)
Bispecific antibodies in indolent lymphomas - A. Conconi (Biella)
Privacy Policy | Cookie Policy